A Phase Ib/II Study of Ivosidenib With Venetoclax plus /- Azacitidine in IDH1Mutated Hematologic Malignancies (2022)
Attributed to:
University of Oxford – Confidence in Concept 2019
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Type: Conference/Paper/Proceeding/Abstract
Volume: 22
Parent Publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
ISSN: 2152-2650